Leukocyte Extracellular Vesicles Predict Progression of Systolic Dysfunction in Heart Failure with Mildly Reduced Ejection Fraction (LYCHEE) - A Prospective, Multicentre Cohort Study

Overview

Journal J Cardiovasc Transl Res

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2024 Sep 24

PMID 39316271

Authors

Aleksandra Gasecka

Aleksander Siniarski

Piotr Duchnowski

Konrad Stepien

Ewelina Blazejowska

Magdalena Gajewska

Kacper Karaban

Kinga Porebska

Aleksandra Reda

Sylwester Rogula

Bartosz Rolek

Dorota Slupik

Roksana Gozdowska

Marcin Kleibert

Dominika Zajkowska

Michal Grat

Marcin Grabowski

Krzysztof J Filipiak

Edwin van der Pol

Rienk Nieuwland

Affiliations

Soon will be listed here.

Abstract

Risk stratification in heart failure with mildly-reduced ejection fraction (HFmrEF) remains challenging. We evaluated the predictive value of advanced glycation end products (AGEs) and plasma concentrations of extracellular vesicles (EVs) for the systolic and diastolic dysfunction progression in HFmrEF patients. Skin AGE accumulation was measured using AGE Reader. Plasma EV concentrations were measured using flow cytometry. Among 74 patients enrolled, 13 (18%) had systolic dysfunction progression and 5 (7%) had diastolic dysfunction progression during 6.5 months follow-up. Leukocyte EVs concentrations were higher in patients with systolic dysfunction progression (p = 0.002) and predicted the progression with 75.0% sensitivity and 58.3% specificity, independent of other clinical variables (OR 4.72, 95% CI 0.99-22.31). Skin AGE levels and concentrations of other EV subtypes were not associated with systolic or diastolic dysfunction progression. Increased leukocyte EVs concentrations are associated with 4.7-fold higher odds of systolic dysfunction progression in HFmrEF patients.

References

Schafer S, Huber J, Wihler C, Rutten H, Busch A, Linz W . Impaired left ventricular relaxation in type 2 diabetic rats is related to myocardial accumulation of N(epsilon)-(carboxymethyl) lysine. Eur J Heart Fail. 2005; 8(1):2-6. DOI: 10.1016/j.ejheart.2005.04.011. View

Nagueh S, Smiseth O, Appleton C, Byrd 3rd B, Dokainish H, Edvardsen T . Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016; 29(4):277-314. DOI: 10.1016/j.echo.2016.01.011. View

Arauna D, Chiva-Blanch G, Padro T, Fuentes E, Palomo I, Badimon L . Frail older adults show a distinct plasma microvesicle profile suggesting a prothrombotic and proinflammatory phenotype. J Cell Physiol. 2020; 236(3):2099-2108. DOI: 10.1002/jcp.29996. View

Lucien F, Gustafson D, Lenassi M, Li B, Teske J, Boilard E . MIBlood-EV: Minimal information to enhance the quality and reproducibility of blood extracellular vesicle research. J Extracell Vesicles. 2023; 12(12):e12385. PMC: 10704543. DOI: 10.1002/jev2.12385. View

Kou Y, Zou L, Liu R, Zhao X, Wang Y, Zhang C . Intravascular cells and circulating microparticles induce procoagulant activity via phosphatidylserine exposure in heart failure. J Thromb Thrombolysis. 2019; 48(2):187-194. DOI: 10.1007/s11239-019-01889-8. View

Smit A, Hartog J, Voors A, Van Veldhuisen D . Advanced glycation endproducts in chronic heart failure. Ann N Y Acad Sci. 2008; 1126:225-30. DOI: 10.1196/annals.1433.038. View

Vilella-Figuerola A, Cordero A, Mirabet S, Munoz-Garcia N, Suades R, Padro T . Platelet-Released Extracellular Vesicle Characteristics Differ in Chronic and in Acute Heart Disease. Thromb Haemost. 2023; 123(9):892-903. DOI: 10.1055/s-0043-57017. View

Tripisciano C, Weiss R, Eichhorn T, Spittler A, Heuser T, Fischer M . Different Potential of Extracellular Vesicles to Support Thrombin Generation: Contributions of Phosphatidylserine, Tissue Factor, and Cellular Origin. Sci Rep. 2017; 7(1):6522. PMC: 5529579. DOI: 10.1038/s41598-017-03262-2. View

Bidasee K, Zhang Y, Shao C, Wang M, Patel K, Dincer U . Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2+-ATPase. Diabetes. 2004; 53(2):463-73. DOI: 10.2337/diabetes.53.2.463. View

10.

Gasecka A, Pluta K, Solarska K, Rydz B, Eyileten C, Postula M . Plasma Concentrations of Extracellular Vesicles Are Decreased in Patients with Post-Infarct Cardiac Remodelling. Biology (Basel). 2021; 10(2). PMC: 7910841. DOI: 10.3390/biology10020097. View

11.

Chironi G, Simon A, Hugel B, Del Pino M, Gariepy J, Freyssinet J . Circulating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol. 2006; 26(12):2775-80. DOI: 10.1161/01.ATV.0000249639.36915.04. View

12.

Zhang Y, Vernooij F, Ibrahim I, Ooi S, Gijsberts C, Schoneveld A . Extracellular Vesicle Proteins Associated with Systemic Vascular Events Correlate with Heart Failure: An Observational Study in a Dyspnoea Cohort. PLoS One. 2016; 11(1):e0148073. PMC: 4731211. DOI: 10.1371/journal.pone.0148073. View

13.

Heidland A, Sebekova K, Frangiosa A, De Santo L, Cirillo M, Rossi F . Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation. Heart. 2004; 90(11):1269-74. PMC: 1768553. DOI: 10.1136/hrt.2003.026989. View

14.

Coumans F, Brisson A, Buzas E, Dignat-George F, Drees E, El-Andaloussi S . Methodological Guidelines to Study Extracellular Vesicles. Circ Res. 2017; 120(10):1632-1648. DOI: 10.1161/CIRCRESAHA.117.309417. View

15.

Zeng C, Li Y, Ma J, Niu L, Tay F . Clinical/Translational Aspects of Advanced Glycation End-Products. Trends Endocrinol Metab. 2019; 30(12):959-973. DOI: 10.1016/j.tem.2019.08.005. View

16.

Altamura M, DAndrea G, Angelini E, Tortorelli F, Balzotti A, Porcelli P . Psychosomatic syndromes are associated with IL-6 pro-inflammatory cytokine in heart failure patients. PLoS One. 2022; 17(3):e0265282. PMC: 8912235. DOI: 10.1371/journal.pone.0265282. View

17.

Vilella-Figuerola A, Padro T, Roig E, Mirabet S, Badimon L . New factors in heart failure pathophysiology: Immunity cells release of extracellular vesicles. Front Cardiovasc Med. 2022; 9:939625. PMC: 9669903. DOI: 10.3389/fcvm.2022.939625. View

18.

Gasecka A, Nieuwland R, Budnik M, Dignat-George F, Eyileten C, Harrison P . Randomized controlled trial protocol to investigate the antiplatelet therapy effect on extracellular vesicles (AFFECT EV) in acute myocardial infarction. Platelets. 2018; 31(1):26-32. DOI: 10.1080/09537104.2018.1557616. View

19.

van Niel G, DAngelo G, Raposo G . Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018; 19(4):213-228. DOI: 10.1038/nrm.2017.125. View

20.

Hartog J, Voors A, Bakker S, Smit A, Van Veldhuisen D . Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail. 2007; 9(12):1146-55. DOI: 10.1016/j.ejheart.2007.09.009. View